FDA Inspection
Hospira, Inc., A Pfizer CompanyHospira, Inc., A Pfizer Company – FDA Inspection, Jun 8, 2016
Record Details
This FDA Inspection record concerns Hospira, Inc., A Pfizer Company, with an inspection on June 8, 2016, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- June 8, 2016
- Product Type
- Drugs
View Company Profile
ID · a5714d8e-e4a7-4480-9258-6cca2d3240b1
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 976095
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Hospira, Inc., A Pfizer Company
19| Date | Classification | Office | Project area |
|---|---|---|---|
| March 10, 2026 | Not classified | Kansas City District Office | |
| January 17, 2025 | VAI | Kansas City District Office | Drug Quality Assurance |
| March 27, 2024 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| June 30, 2023 | Not classified | Kansas City District Office | |
| January 17, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Hospira, Inc., A Pfizer Company
- FDA Inspection 1310592 - 2026-03-10
- FDA Inspection 1255699 - 2025-01-17
- FDA Inspection 1229140 - 2024-03-27
- FDA Inspection 1209308 - 2023-06-30
- FDA Inspection 1115467 - 2020-01-17
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.